Codexis, Inc.  

(Public, NASDAQ:CDXS)   Watch this stock  
Find more results for CDXS
4.12
+0.91 (28.35%)
After Hours: 4.12 0.00 (0.00%)
Aug 4, 7:32PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.81 - 4.25
52 week 1.94 - 5.65
Open 3.81
Vol / Avg. 718,391.00/78,137.00
Mkt cap 128.03M
P/E     -
Div/yield     -
EPS -0.48
Shares 39.88M
Beta 0.80
Inst. own 57%
Aug 4, 2015
Q2 2015 Codexis Inc Earnings Release (Estimated)
Aug 4, 2015
Codexis, Inc. Business Update Call - Webcast
Jun 11, 2015
Codexis Inc Annual Shareholders Meeting (Estimated)
May 7, 2015
Q1 2015 Codexis Inc Earnings Call - Webcast
May 7, 2015
Q1 2015 Codexis Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -81.82% -54.01%
Operating margin -81.33% -54.13%
EBITD margin - -44.57%
Return on average assets -49.83% -35.66%
Return on average equity -93.09% -56.26%
Employees 91 -
CDP Score - -

Address

200 Penobscot Dr
REDWOOD CITY, CA 94063-4718
United States - Map
+1-650-4218100 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Codexis, Inc. is a developer of biocatalysts. The Company is engaged in the pharmaceutical and fine chemical industries. The Company's CodeEvolver protein engineering technology platform is used in the evolution and optimization of biocatalysts to perform specific and desired chemical reactions at commercial scale. The pharmaceutical customers use its technology, products and services in their manufacturing process development and production of drugs. The Company's technologies enable scale-up and implementation of biocatalytic solutions for sustainable process development, from research to manufacturing. The Company's products include Codex screening panels and kits that enable customers to establish optimal reactions. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates and Codex Biocatalyst Kits and Panels.

Officers and directors

Thomas R. Baruch J.D. Independent Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
John J. Nicols President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Gordon T. Sangster Chief Financial Officer, Senior Vice President
Age: 60
Bio & Compensation  - Reuters
Douglas T. Sheehy J.D. Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Pam P. Cheng Director
Bio & Compensation  - Reuters
Kathleen Sereda Glaub Director
Age: 51
Bio & Compensation  - Reuters
Patrick Y. Yang Ph.D. Director
Age: 67
Bio & Compensation  - Reuters
Byron L. Dorgan Independent Director
Age: 71
Bio & Compensation  - Reuters
Alexander A. Karsner Independent Director
Age: 47
Bio & Compensation  - Reuters